Evotec is particularly focused on expanding its biologics capabilities to meet increased demand for complex biologics manufacturing and broaden its offerings to customers. We expect the company will ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...

“We were given the opportunity to engage with Genentech in 1977, two years before its IPO [initial public offering], and we ...